Approximately 15,000 new patients are diagnosed every year in the United States, the majority of which are misdiagnosed before having access (not because of financial reasons) to a sarcoma specialist. Compared with the more common cancers, sarcomas have not been extensively investigated, due to the fact that funds for research are virtually nonexistent.  This is because the pharmaceuticals companies consider the number of patients with sarcoma extremely low (as compared with the double digit millions for other cancers).   Thus they have no profit incentive to develop clinical trials or chemos for sarcoma patients. The result is very limited treatment options for sarcoma patients. Sarcoma remains as one of the most deadly forms of cancer amongst children and adults.  The factors responsible for the disease are unknown.